Gå direkt till huvudinnehållet

ADHD/hyperaktivitetsstörningar hos barn

Senast uppdaterad: Senast reviderad:
Sakkunnig:


Definition:
Tillstånd präglat av störningar i koncentrations-/uppmärksamhetsförmågan och/eller motorisk hyperaktivitet och impulsivitet. Tillståndet måste föreligga i minst sex månader. Symtomen ska ha noterats före tolv års ålder och ha en direkt negativ inverkan på sociala aktiviteter och aktiviteter inom studier/arbete.
Förekomst:
Prevalensen för ADHD bland barn är 3 %.
Symtom:
Huvudsymtom är störningar i koncentration och uppmärksamhet, motorisk hyperaktivitet och ökad impulsivitet.
Kliniska fynd:
Symtomen leder ofta till beteendestörningar och dålig funktion socialt och i skolan.
Diagnostik:
Diagnos ställs inom den barnpsykiatriska vården efter en grundlig utredning.
Behandling:
Multimodal behandling med pedagogiska, psykologiska/psykiatriska, medicinska och psykosociala åtgärder.
  1. Verkuijl N, Perkins M, Fazel M. Childhood attention-deficit/hyperactivity disorder. BMJ. 2015 May 20;350:h2168. doi: 10.1136/bmj.h2168. PMID: 25994532. PubMed  
  2. American Psychiatric Association. MINI-D 5. Diagnostiska kriterier enligt DSM-5. Stockholm: Pilgrim Press AB, 2015.
  3. Willams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010; 376: 1401 - 1408. PubMed  
  4. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237-48. PubMed  
  5. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016. pmid:26386541 PubMed  
  6. BUSA BehandlingsUppföljning av Säkerställd ADHD. Årsrapport 2015. www.psykiatriregister.se  
  7. Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010; 376: 1401-8 PubMed  
  8. Doyle R. The history of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 2004; 27: 203-14. PubMed  
  9. Scahill L and Schwab-Stone M. Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 2000; 9: 541-55. PubMed  
  10. Faraone SV, Perlis RH, Doyle AE et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313-23. PubMed  
  11. Sprich S, Biederman J, Crawford MH, Mundy E and Faraone SV. Adoptive and biological families of children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2000; 39: 1432-7. PubMed  
  12. Carlsson T, Molander F, Taylor MJ, Jonsson U, Bölte S. Early environmental risk factors for neurodevelopmental disorders - a systematic review of twin and sibling studies published online ahead of print, 2020 Jul 24. Dev Psychopathol. 2020;1-48. PMID: 32703331 PubMed  
  13. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet 2005; 366: 237-48. PubMed  
  14. Sonuga-Barke EJ. Casual models of Attention-deficit/hyperactivity disorder: from common simple deficits to multiple developmental pathways. Biol Psychiatry 2005; 57: 1231-8. PubMed  
  15. Hoogman M, Bralten J, Hibar DP et al. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: a cross-sectional mega-analysis. The Lancet Psychiatry , 2017. www.thelancet.com  
  16. Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH and Lee JD. Dopamine transporter density in the basal ganglia assessed with 123IIPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imag 2003; 30: 306-11. PubMed  
  17. Gilberg C, Gilberg IC, Rasmussen P, et al. Co-existing disorders in ADHD - implication for diagnosis and intervention. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 80-92 PMID: 15322959. PubMed  
  18. Faraone SV, Biederman J and Zimmerman BA. Correspondence of parent and teacher reports in medication trials. Eur J Child Adolesc Psychiatry 2005; 14: 20-7. PubMed  
  19. Green M, Wong M, Atkins D, et al. Diagnosis of Attention-Deficit/Hyperactivity Disorder. Systematic review. Rockville: US Department of Health and Human Services, ACHPR Publication 1999. PMID: 20734519. PubMed  
  20. Murphy KR, Barkley RA and Bush T. Young adults with attention deficit hyperactivity disorder: subtype differences in comorbidity, educational, and clinical history. J Nerv Ment Dis 2002; 190: 147-57. PubMed  
  21. Bird H, Gould M and Staghezza-Jaramillo B. The comorbidity of ADHD in a community sample of children aged 6 through 16 years. J Child Fam Stud 1994; 3: 365-78. PubMed  
  22. Kadesjo B and Gillberg C. The comorbidity of ADHD in the general population of Swedish school-age children. J Child Psychol Psychiatry 2001; 42: 487-92. PubMed  
  23. Sowell ER, Thompson PM, Welcome SE, et al. Cortical abnormalities in children and adolescents with attention-deficit hyperactivity disorder. Lancet 2003; 362: 1699-707. PubMed  
  24. Stöd till barn, ungdomar och vuxna med adhd – ett kunskapsstöd. Socialstyrelsen (2014). www.socialstyrelsen.se  
  25. Southammakosane C, Schmitz K, et al. Pediatric Psychopharmacology for Treatment of ADHD, Depression, and Anxiety. Pediatrics. 2015 Aug;136(2):351-9. PubMed  
  26. Läkemedel vid adhd - behandlingsrekommendation. Läkemedelsverket 2015. lakemedelsverket.se  
  27. https://lakemedelsverket.se/upload/halso-och-sjukvard/behandlingsrekommendationer/Lakemedel_%20vid_adhd_behandlingsrekommendation.pdf lakemedelsverket.se  
  28. Storebø OJ, Ramstad E, Krogh HB, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2015; 11: CD009885. pmid:26599576 PubMed  
  29. The MTA Cooperative Group. National Institute of Mental Health Multimodal treatment study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004; 113: 762-9. PMID: 15060225. PubMed  
  30. The MTA Cooperative Group. National Institute of Mental Health Multimodal treatment study of ADHD follow-up: 24 month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics 2004; 113: 754-61. PMID: 15060224. PubMed  
  31. Matthijssen AM, Dietrich A, Bierens M et al. Continued Benefits of Methylphenidate in ADHD After 2 Years in Clinical Practice: A Randomized Placebo-Controlled Discontinuation Study. Am J Psychiatry 2019. pmid:31109200 PubMed  
  32. Sömnstörningar hos barn – kunskapsdokument. Läkemedelsverket (2015). www.lakemedelsverket.se  
  33. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-8. PubMed  
  34. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011; 365: e-pub. PMID: 22043968. PubMed  
  35. Stuhec M, Munda B, Svab V, et al. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord. 2015 Jun 1;178:149-59. PubMed  
  36. Punja S, Shamseer L, Hartling L et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2016; Feb 4;2: CD009996. pmid:26844979. PubMed  
  37. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009;11(3):203-26. PubMed  
  38. Banaschewski T, Roessner V, Dittmann R, et al. Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004; 13 (Suppl 1): 102-16.PMID: 15322961 PubMed  
  39. Perwien AR, Faries DE, Kratochvil J, et al. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine. Developmental and Behavioral Pediatrics 2004; 25: 264-71. PubMed  
  40. Kratochvil CJ, Heiligenstein JH, Dittmann R et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002; 41: 776-84. PubMed  
  41. Starr LH, Kemner JE, Ciccone PE et al. Comparison of treatment outcomes in children with ADHD: a discussion on the Formal Observation of Concerta® versus Strattera® (FOCUS) study. J Nat Med Ass 2004; 96: 876. PubMed  
  42. Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J. Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 2005; 116: e74-e80. PMID: 15995021. PubMed  
  43. Cortese S, Ferrin M, Brandeis D, et al. Cognitive training for attention-deficit/hyperactivity disorder: meta-analysis of clinical and neuropsychological outcomes from randomized controlled trials. J Am Acad Child Adolesc Psychiatry. 2015 Mar;54(3):164-74. Epub 2014 Dec 29.pmid: 25721181. PubMed  
  44. Nigg J, Lewis K, Edinger T, Falk M. Meta-Analysis of Attention-Deficit/Hyperactivity Disorder or Attention-Deficit/Hyperactivity Disorder Symptoms, Restriction Diet, and Synthetic Food Color Additives. J Am Acad Child Adolesc Psychiatry 2012; Jan; 51(1): 86–97. pmid:4321798. PubMed  
  45. Weber W, Stoep AV, McCarty RL et al. Hypericum perforatum (St John's Wort) for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. JAMA 2008; 299: 2633-41. PMID: 18544723. PubMed  
  46. SBU:s upplysningstjänst 2013-03-27: "Kan melatonin minska sömnproblem hos barn med ADHD?" www.sbu.se  
  47. Edbom T, Lichtenstein P, Granlund M og Larsson JO. Long-term relationship between symptoms of Attention Deficit Hyperactivity Disorder and self-esteem in a prospective longitudinal study of twins. Acta Pædiatrica 2006; 95: 650-7. PubMed  
  48. Modestin J, Matutat B and Wurmle O. Antecedents of opioid dependence and personality disorder: attention-deficit/hyperactivity disorder and conduct disorder. Eur Arch Psychiatry Clin Neurosci 2001; 251: 42-7. PubMed  
  49. Katz LJ, Goldstein G and Geckle M. Neuropsychological and personality differences between men and women with ADHD. J Attent Disord 1998; 2: 239-47. PubMed  
  50. DiScala C, Lescohier I, Barthel M and Li G. Injuries to children with attention deficit hyperactivity disorder. Pediatrics 1998; 102: 1415-21. PMID: 9832578. PubMed  
  51. Biederman J, Monuteaux M, Seidman L et al. Impact of executive function deficits and ADHD on academic outcomes in children. J Consult Clin Psychol 2004; 72: 757-66. PubMed  
  52. Steinhausen HC, Drechsler R, Foldenyi M, Imhof K and Brandeis D. Clinical course of attention-deficit/hyperactivity disorder from childhood toward early adolescence. J Am Acad Child Adolesc Psychiatry 2003; 42: 1085-92. PubMed  
  53. Kooij SJJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: The European network adult ADHD. BMC Psychiatry 2010; 10: 69. PMID: 20815868. PubMed  
  54. Kunskapsdokument Svenska psykiatriska föreningen. Regionalt vårdprogram ADHD, lindrig utvecklingsstörning och autismspektrumtillstånd hos barn, ungdomar och vuxna. Stockholms läns landsting 2010. www.svenskpsykiatri.se  
  • Anna Nager, med dr och specialist i allmänmedicin, Karolinska institutet
  • Kerstin Malmberg, med dr och överläkare, BUP Stockholm sektion Västra Skärholmen